New drug talquetamab targets Hard-to-Treat myeloma in first human trial

NCT ID NCT03399799

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This early-stage trial tests a new drug called talquetamab in 279 people with multiple myeloma that has come back or stopped responding to other treatments. Talquetamab is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check safety and find the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Talquetamab (a bispecific antibody that helps immune cells attack cancer)
What this could lead to: If successful, this could provide a new treatment option for people with multiple myeloma who have run out of standard therapies.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, so it is not yet proven to work. Side effects, including serious immune reactions, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES

Contacts and locations

Locations

Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

Liège, 4000, Belgium
City of Hope

Duarte, California, 91010, United States
Clinica Univ. de Navarra

Pamplona, 31008, Spain
Hosp Clinico Univ de Salamanca

Salamanca, 37007, Spain
Hosp Univ Fund Jimenez Diaz

Madrid, 28040, Spain
Hosp. Quiron Madrid Pozuelo

Pozuelo de Alarcón, 28223, Spain
Hosp. Univ. Germans Trias I Pujol

Badalona, 08916, Spain
Mount Sinai Medical Center

New York, New York, 10029, United States
Tennessee Oncology

Nashville, Tennessee, 37203, United States
UMCU

Utrecht, 3584 CX, Netherlands
University of Alabama Birmingham

Birmingham, Alabama, 35294, United States
University of Colorado Cancer Center

Aurora, Colorado, 80045, United States
VU Medisch Centrum

Amsterdam, 1081 HV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.